Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Theralase Technologies Inc is a clinical stage pharmaceutical company. It is dedicated to the research and development of light activated Photo Dynamic Compounds, their associated drug formulations and technology platforms intended to safely and effectively; treat various cancers, bacteria and viruses. The Cool Laser Technology division designs, develops, manufactures and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, primarily in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.
Toronto, ON, M4B 3G4, Canada